Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Business Wire
- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration partner RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe to severe hemophilia A that it has co-developed with, and licensed to Pfizer Inc., following a decision by Pfizer to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner. Pfizer has indicated to Sangamo that this termination reflects its decision not to proceed with the Biologics License Application (BLA) and Marketing A
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their RightsAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMOAccesswire
- SGMO ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Sangamo Therapeutics, Inc. investmentAccesswire
- Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to ConnectAccesswire
- SGMO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sangamo Therapeutics, Inc. Shareholders Who Lost MoneyAccesswire
SGMO
Earnings
- 11/12/24 - Beat
SGMO
Sec Filings
- 12/30/24 - Form 8-K
- 12/10/24 - Form 8-K
- 11/26/24 - Form 4
- SGMO's page on the SEC website